5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.08▼ | 2.08▼ | 2.08▼ | 2.03▼ | 2.10▼ |
MA10 | 2.12▼ | 2.12▼ | 2.12▼ | 2.09▼ | 2.10▼ |
MA20 | 2.15▼ | 2.14▼ | 2.14▼ | 2.12▼ | 2.05▼ |
MA50 | 2.22▼ | 2.18▼ | 2.13▼ | 2.07▼ | 2.04▼ |
MA100 | 2.08▼ | 2.09▼ | 2.11▼ | 2.03▼ | 2.33▼ |
MA200 | 2.17▼ | 2.11▼ | 2.07▼ | 2.00▼ | 2.89▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.017▼ | -0.018▼ | -0.021▼ | -0.032▼ | 0.005▲ |
RSI | 34.322▼ | 36.198▼ | 37.615▼ | 32.761▼ | 45.629▼ |
STOCH | 28.345 | 28.345 | 28.345 | 35.935 | 51.611 |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -92.990▼ | -76.525▼ |
CCI | -171.731▼ | -173.965▼ | -173.965▼ | -196.526▼ | -49.316 |
Thursday, June 12, 2025 10:45 PM
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its ...
|
Thursday, June 12, 2025 05:00 PM
The latest price target for Innate Pharma (NASDAQ:IPHA) was reported by HC Wainwright & Co. on April 24, 2025. The analyst firm set a price target for $11.00 expecting IPHA to rise to within 12 ...
|
Monday, May 26, 2025 01:20 AM
Innate Pharma S.A. (NASDAQ:IPHA) Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Hello and thank you for standing by. My name is Regina and will be your conference operator today.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 1.96 | 1.98 | 1.8705 | 1.895 | 12,580 |
12/06/25 | 2.00 | 2.00 | 1.95 | 1.975 | 7,057 |
11/06/25 | 2.02 | 2.02 | 1.94 | 2.0112 | 10,717 |
09/06/25 | 2.15 | 2.15 | 2.0701 | 2.08 | 4,131 |
06/06/25 | 2.18 | 2.19 | 2.1328 | 2.17 | 9,610 |
05/06/25 | 2.195 | 2.21 | 2.02 | 2.15 | 13,662 |
04/06/25 | 2.195 | 2.195 | 2.14 | 2.14 | 3,848 |
03/06/25 | 2.15 | 2.15 | 2.12 | 2.13 | 6,412 |
02/06/25 | 2.14 | 2.18 | 2.14 | 2.1578 | 3,163 |
30/05/25 | 2.2099 | 2.2099 | 2.0616 | 2.19 | 8,120 |
|
|
||||
|
|
||||
|
|